220 related articles for article (PubMed ID: 37841254)
41. The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes.
Shokrgozar N; Dehghani M; Golmoghaddam H; Moghadam M; Rezaei N; Moayed V; Arandi N
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e388-e397. PubMed ID: 35098660
[TBL] [Abstract][Full Text] [Related]
42. Reversal of the CD8
Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
Front Immunol; 2021; 12():687296. PubMed ID: 34177939
[TBL] [Abstract][Full Text] [Related]
43. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
Ann Oncol; 2017 Dec; 28(12):2977-2984. PubMed ID: 29045526
[TBL] [Abstract][Full Text] [Related]
44. CXCR5
Tang J; Zha J; Guo X; Shi P; Xu B
Int Immunopharmacol; 2017 Sep; 50():146-151. PubMed ID: 28662433
[TBL] [Abstract][Full Text] [Related]
45. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.
Zhao L; Liu Y; Zhang J; Liu Y; Qi Q
Cell Death Dis; 2019 Sep; 10(10):731. PubMed ID: 31570691
[TBL] [Abstract][Full Text] [Related]
46. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
47. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
[TBL] [Abstract][Full Text] [Related]
48. Lkb1 aggravates diffuse large B-cell lymphoma by promoting the function of Treg cells and immune escape.
Su X; Sun T; Li M; Xia Y; Li M; Wang D; Lu F; Ye J; Ji C
J Transl Med; 2022 Aug; 20(1):378. PubMed ID: 35986288
[TBL] [Abstract][Full Text] [Related]
49. A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma.
Lee H; Yoon SE; Kim SJ; Kim WS; Cho J
Cancer Med; 2023 Aug; 12(15):16359-16369. PubMed ID: 37326144
[TBL] [Abstract][Full Text] [Related]
50. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
Chen BJ; Dashnamoorthy R; Galera P; Makarenko V; Chang H; Ghosh S; Evens AM
Oncotarget; 2019 Mar; 10(21):2030-2040. PubMed ID: 31007846
[TBL] [Abstract][Full Text] [Related]
51. Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.
Xu T; Chai J; Wang K; Jia Q; Liu Y; Wang Y; Xu J; Yu K; Zhao D; Ma J; Fan L; Yan Q; Guo S; Chen G; Chen Q; Xiao H; Liu F; Qi C; Liang R; Li M; Wang Z
Front Oncol; 2021; 11():638154. PubMed ID: 34221962
[TBL] [Abstract][Full Text] [Related]
52. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
[TBL] [Abstract][Full Text] [Related]
53. Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma.
Ji H; Niu X; Yin L; Wang Y; Huang L; Xuan Q; Li L; Zhang H; Li J; Yang Y; An W; Zhang Q
Cell Physiol Biochem; 2018; 45(3):951-961. PubMed ID: 29428948
[TBL] [Abstract][Full Text] [Related]
54. Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.
Wei T; Li M; Zhu Z; Xiong H; Shen H; Zhang H; Du Q; Li Q
J Cancer Res Clin Oncol; 2021 Mar; 147(3):691-701. PubMed ID: 33389078
[TBL] [Abstract][Full Text] [Related]
55. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
[TBL] [Abstract][Full Text] [Related]
56. [Expression levels of co-inhibitory molecules CTLA-4, LAG-3, PD-1 and CD39 on CD4⁺ T cells correlate with progression of non-small cell lung cancer].
Wei T; Zhang J; Wu Y; Zhang D; Lu L; Shen Q
Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):424-9. PubMed ID: 25241783
[TBL] [Abstract][Full Text] [Related]
57. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
58. MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8
Xu Y; Liu Z; Lv L; Li P; Xiu B; Qian W; Liang A
J Exp Clin Cancer Res; 2020 Nov; 39(1):238. PubMed ID: 33168024
[TBL] [Abstract][Full Text] [Related]
59. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
60. TIGIT is a key inhibitory checkpoint receptor in lymphoma.
Godfrey J; Chen X; Sunseri N; Cooper A; Yu J; Varlamova A; Zarubin D; Popov Y; Jacobson C; Postovalova E; Xiang Z; Nomie K; Bagaev A; Venkataraman G; Zha Y; Tumuluru S; Smith SM; Kline JP
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
